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PES2
ASSOCIATION BETWEEN MORTALITY AND VISUAL
IMPAIRMENT ESTIMATED FROM A FRENCH NATIONAL
SURVEY
Brézin A1, Lafuma A2, Fagnani F2, Mesbah M3, Berdeaux G4
1Hopital Cochin, Paris, France; 2Cemka, Bourg-La-Reine, France;
3Université de Bretagne-Sud,Vannes, France; 4Alcon, Rueil-Malmaison,
France
OBJECTIVES: To estimate the association between visual
impairment (expressed as low vision (LV) and blindness) and
mortality. METHODS: Two national surveys were pooled
together. First, 2075 institutions for children or adults with
handicaps, the aged, and psychiatric patients were selected at
random, in 18 predeﬁned strata, from French Health Ministry
ﬁles. In total, 15,403 subjects were selected and 14,603 (94.9%)
were interviewed. Second, a random, stratiﬁed sample of
356,208 persons living in the community was selected, of whom
21,760 subjects were further selected, randomly, and 16,945
(77.9%) were interviewed. Three groups were identiﬁed, based
on personal interviews: blind, LV, and a control group (CG). Two
years later, 14,497 subjects in institutions and 15,648 in the com-
munity were questioned again. Data on death were obtained
from either the national register or households. Death rates were
estimated by age, gender and visual impairment. Weights for
national extrapolation came from the 1999 national census. A
logistic stepwise regression was used to adjust for other handi-
caps, activity of daily living (ADL), age-squared by gender inter-
action, and institution versus community residence. RESULTS:
The average age of subjects was 38.3 years, 48.60% were male
and 1.15% lived in institutions. The death rate (1.76% over 2
years) increased exponentially with age and male gender. This
last interaction explained most of the variance and ADL
accounted for the balance. The probability of dying was higher
in subjects with handicaps: visceral (odds ratio[OR] = 2.83),
speech (OR = 2.10), brain (OR = 1.53), motor function (OR =
1.42), or auditory (OR = 1.39). Visual impairment was signiﬁ-
cantly (p < 0.0001) associated with increased risk of mortality
(blindness: OR = 2.79; LV: OR = 2.06). CONCLUSIONS: Visual
impairment is an independent factor associated with mortality.
PES3
ANALYSIS OF CLINICAL EFFICACY OF LATANOPROST VS.
THE MOST FREQUENT TREATMENT PATTERN FOR PRIMARY
OPEN ANGLE GLAUCOMA (POAG) AND OCULAR
HYPERTENSION (OH) IN POLAND
Walczak J1, Pajor A1, Kaczor M1,Wcislo J2
1Arcana Institute, Krakow, Poland; 2Pﬁzer, Warsaw, Poland
OBJECTIVES: The aim of the study was comparing latanoprost
treatment with the most frequent therapy pattern for POAG and
OH in Poland. The most frequently prescribed drug for treat-
ment of POAG and OH in Poland is dorzolamide, representing
30% of total prescriptions. Approximately 25% of prescriptions
for POAG represent dorzolamide in polytherapy, the most fre-
quent combination with timolol represents 9% of total pre-
scriptions. METHODS: We assessed current treatment patterns
of POAG and OH based on IMS Health Data from Poland
(MAT/ September, 2003). The clinical efﬁcacy analysis was based
on the systematic review in accordance with methodological
survey rules based on Cochrane Reviewer’s Handbook. Data
were extracted from the randomized controlled trials comparing
latanoprost 0.005% once daily vs. dorzolamide t.i.d. and
latanoprost 0.005% vs. dorzolamide 2% + timolol 0.5% b.i.d.
and entered into the Review Manager computer software.
Response to treatment was estimated in accordance with meta-
analysis trials, which included Odds Ratio of the observation of
minimum 10%, 20%, 30%, 40% IOP reduction in relation to a
starting level after 3 months treatment. RESULTS: In a group of
patients treated with latanoprost, the chance of 20%, 30%, 40%
IOP reduction in relation to baseline was statistically higher than
in dorzolamide group in monotherapy: (20% OR = 7.1; 95% CI
3.1 to 59,5), (30% OR = 6.5; 95% CI 3.3 to 12.6), (40% OR
= 7.1; 95% CI 3.6 to 13.9) and also in comparison with com-
bined therapy group (20% OR = 1.7; 95% CI 1.1 to 2.4), (30%
OR = 1.4; 95% CI 0.9 to 2.1), (40% OR = 3.5; 95% CI 1.2 to
10.6). A percentage of patients with general or ocular adverse
effects was lower in groups treated with latanoprost than in
other groups but observed differences were not statistically sig-
niﬁcant. CONCLUSIONS: Use of latanoprost in treatment of
POAG is more effective than the most frequent treatment pattern
in Poland.
PES4
EFFECT OF CIRCADIAN INTRA-OCULAR PRESSURE
VARIATIONS ON THERAPEUTIC DECISION MAKING:
A MODELING APPROACH BASED ON A RANDOMIZED
CLINICAL TRIAL
Dubiner HB1, Berdeaux G2
1Clayton eye center, Morrow, GA, USA; 2Alcon, Rueil-Malmaison,
France
OBJECTIVES: The aim of our model was to estimate the effect
of circadian intra-ocular pressure (IOP) variations on ocular
hypertension diagnosis, treatment changes, nocturnal IOP peak
control, and daily cumulative pressure on the optic nerve head
(ONH). METHODS: Thirty-four glaucoma patients were
included in a double-masked randomized trial. Patients were
treated for 2 weeks with either travoprost 0.004% or latanoprost
0.005%, after a 4-week wash-out. Intra-ocular pressure was
measured every 4 hours during 1 day. The probability of reach-
ing a predeﬁned threshold (success) was calculated from a
normal function. Time spent over an IOP target was calculated
using area-under-the-curve weighted by success rate. The noc-
turnal IOP peak measure was estimated using a stepwise regres-
sion predicting the maximal night IOP as a function of day-time
IOP measures. Sensitivity analyses were performed. RESULTS:
Before treatment, IOP was more elevated in the morning than
the evening. The probability of an IOP exceeding the target value
of a diagnosis or therapy varied throughout the day. The IOP
variance was an important factor, regardless of the actual IOP
value. Travoprost controlled IOP better than latanoprost at
16:00 and 20:00. More patients (up to 34.5%) would reach the
IOP target with travoprost. Cumulative time spent above a target
IOP was lower (up to 2.7 hours) with travoprost. Diurnal IOP
measured at 16:00 was the single most predictive IOP measure
of nocturnal peaks. Travoprost would be better at controlling
these IOP ﬂuctuations (relative risk up to 1.34). CONCLU-
SIONS: The data suggest that 1) ocular hypertension diagnosis
and therapeutic decisions should be made early in the morning;
and 2) daily IOP control should protect against the deleterious





A COST-EFFECTIVENESS ANALYSIS OF LATANOPROST IN
THE TREATMENT OF OPEN ANGLE GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pﬁzer SA, Alcobendas, Madrid, Spain
OBJECTIVES: Glaucoma is a chronic disease and untreated
leads to progressive loss of vision. Latanoprost has shown good
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intraocular pressure (IOP)-lowering efﬁcacy in patients with
open-angle glaucoma. The purpose of this study was to carry out
a cost-effectiveness analysis of latanoprost versus timolol,
bimatoprost and travoprost in the treatment of glaucoma in
Spain. METHODS: A cost-effectiveness analysis was performed
by building a decision analytical model. Effectiveness data (treat-
ment success was deﬁned as patient with successful IOP control:
£18mmHg) were obtained from published clinical trials mea-
suring IOP-lowering of drugs under evaluation. Health care
resource utilization was taken from the aforementioned clinical
trials and a local expert panel. Only direct medical costs were
included in the model (drug acquisition, diagnostic procedures,
ophthalmologist visits and treatment of therapeutic failures).
Drug acquisition cost data were obtained from ofﬁcial sources
while the rest of the data were taken from a national health care
costs database. The perspective selected for this analysis was the
National Health Service and the time horizon chosen was for 6
months, the time that patients were included in most of the clin-
ical trials found. RESULTS: Cost per patient associated with the
use of timolol, latanoprost, bimatoprost and travoprost was
368€, 379.5€, 377€, and 383€, respectively while their cost/effec-
tiveness ratio was 1116, 702, 785, and 912€ per each patient
with a treatment success. The incremental cost-effectiveness ratio
of using latanoprost compared to timolol, bimatoprost and
travoprost was 54, 40, and -32€ per each additional patient
achieving optimal IOP control. CONCLUSIONS: The results of
this pharmacoeconomic model demonstrates that latanoprost is
a more cost-effective option than the rest of evaluated alterna-
tives. Therefore, latanoprost should be considered as the thera-
peutic option to be selected routinely in the treatment of
open-angle glaucoma in Spain.
PES6
COST EFFECTIVENESS OF LATANOPROST IN FIRST LINE
TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA IN 
THE UK
Gosden T1, Costello S2, Orme ME2, Howard P2, Dooley JA1
1Pﬁzer Ltd,Tadworth, UK; 2Heron Evidence Development, Letchworth
Garden City, UK
OBJECTIVES: To estimate the cost effectiveness of ﬁrst-line
latanoprost treatment for POAG compared with beta-blockers,
travoprost or bimatoprost using a previously developed eco-
nomic model. METHODS: A decision analytical model was
developed where POAG patients either receive latanoprost, beta-
blockers, travoprost or bimatoprost as ﬁrst-line therapy. Subse-
quent therapy switches were determined by average time that
patients persisted with each therapy. Persistency data was
obtained from a retrospective cohort study (Reardon, 2004). IOP
controlled days are estimated from this by assuming that switch-
ing therapy implies failure to control IOP for half the time on
therapy. Resource use was obtained from UK expert opinion and
included ophthalmologist consultations, drug usage and glau-
coma surgery. The NHS perspective was taken and included
direct costs only (NHS 2002 reference costs inﬂated to 2003
prices using HCHS inﬂation index, PSSRU 2003, MIMS 2004).
A one-year time horizon was used to capture all relevant resource
use and to assess main clinical outcomes. RESULTS: The model
estimates that for a cohort of 1000 patients, ﬁrst-line treatment
with latanoprost results in 10,397, 14,341, and 17,142 more
days of IOP control than patients treated initially with a beta-
blocker, travoprost or bimatoprost respectively. Compared with
beta-blockers, ﬁrst-line latanoprost therapy reduces management
and surgical costs. Overall treatment costs are higher for travo-
prost (£29,597 more) and bimatoprost (£36,650 more) com-
pared with ﬁrst-line latanoprost therapy due to higher rates 
of subsequent therapy and surgery. CONCLUSIONS: Overall,
compared to other prostaglandins and beta-blockers, latanoprost
ﬁrst-line therapy results in greater beneﬁt to patients in terms of
more days of IOP control. Latanoprost ﬁrst-line therapy com-
pared with travoprost and bimatoprost results in greater persis-
tency and lower costs.
PES7
A PHARMACOECONOMIC ANALYSIS OF THE FIXED
COMBINATION LATANOPROST/TIMOLOL VERSUS
DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF PATIENTS
WITH GLAUCOMA IN SPAIN
Soto J, De Miguel V
Pﬁzer SA, Alcobendas, Madrid, Spain
OBJECTIVES: Latanoprost/timolol is one of the ﬁxed-combina-
tion more used in daily medical practice to treat glaucoma. The
aim of this analysis is to carry out a pharmacoeconomic evalu-
ation of two ﬁxed-combinations: latanoprost/timolol (L-T) com-
pared to dorzolamide/timolol (D-T) as second line treatment 
in patients with glaucoma in Spain. METHODS: A cost-
effectiveness analysis was performed by building a decision ana-
lytic model. Effectiveness data (patient with an IOP reduction at
least of >25%) were obtained from a multicenter-randomized
trial showing that the L-T combination had signiﬁcantly better
efﬁcacy in reducing IOP than D-T combination[1]. Health care
resource utilisation was taken from the aforementioned clinical
trial and a local expert panel. Only direct medical costs were
included in the model. Drug acquisition costs were obtained
from ofﬁcial sources, while the rest of data were taken from a
national health care-cost database. The perspective selected for
this analysis was the National Health Service and the time
horizon chosen was for 3 months, the time that patients were
followed up in the referenced clinical trial. RESULTS: The per-
centage of patients with a good control of IOP was higher 
with L-T combination (80 vs 65%, p < 0.01) and the cost/
effectiveness ratio was lower with L-T combination than with D-
T combination: 719 vs 840€ per each patient with a treatment
success. The incremental cost-effectiveness ratio of using L-T
combination compared to D-T combination was 196€ per each
additional patient achieving optimal IOP control. CONCLU-
SIONS: This model demonstrates that L-T combination is a more
efﬁcient therapeutic option than D-T combination. Therefore, L-
T combination should be considered as the second line therapy
to be selected routinely when IOP cannot be reduced appropri-
ately with only a drug in Spain. [1] Shin DH, Feldman RM, Sheu
W-P. Ophthalmology 2004;111:276–82.
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RESOURCE UTILIZATION OF END-STAGE GLAUCOMA
PATIENTS RECEIVING LOW VISION CARE: A US MULTI-SITE
RETROSPECTIVE STUDY
Williams RT1, O’Connell WF2,Walt JG3, Siegartel LR4, Katz LM4,
Doyle JJ4
1Deicke Center for Visual Rehabilitation, Wheaton, IL, USA; 2State
College of Optometry, State University of New York, New York, NY,
USA; 3Allergan Inc. USA, Irvine, CA, USA; 4Analytica International,
New York, NY, USA
OBJECTIVES: To estimate resource utilization and costs of end-
stage glaucoma patients receiving low vision care (LVC) via a
multi-center retrospective cohort design. METHODS: A random
sample of 61 open-angle glaucoma charts from 2 US LVC 
facilities with ophthalmologic follow-up was retrospectively
reviewed. Patients with a diagnosis of primary open-angle glau-
coma were followed for at least two years within the time
window from 1998–2003. Clinical and economic data were
abstracted beginning with initial low vision visit. Clinical data
collected included: patient demographics, baseline medical and
